SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Scott C Quinlan, Jennifer C.L Hawes, Daniel Mines, Shirin Ahmed, Stephan Lanes, Vinay Mehta, Crystal N Holick, Nancy Santanello, T Christopher Mast, Performance of an administrative claims algorithm to estimate the incidence of pure red cell aplasia in chronic hepatitis C patients, Epidemiology Reports, 2015, 3, 1, 1

    CrossRef

  2. 2
    EASL Clinical Practice Guidelines: Management of hepatitis C virus infection, Journal of Hepatology, 2014, 60, 2, 392

    CrossRef

  3. 3
    KASL clinical practice guidelines: Management of Hepatitis C, Clinical and Molecular Hepatology, 2014, 20, 2, 89

    CrossRef

  4. 4
    Thierry Thevenot, Thibault Degand, Natacha Grelat, Laure Elkrief, Camille Christol, Richard Moreau, Jean Henrion, Jean-François Cadranel, Frances Sheppard, Christophe Bureau, Vincent Martino, Arnaud Pauwels, A French national survey on the use of antibiotic prophylaxis in cirrhotic patients, Liver International, 2013, 33, 3
  5. 5
    José Antonio Carrión, Elena Gonzalez-Colominas, Montserrat García-Retortillo, Nuria Cañete, Isabel Cirera, Susanna Coll, Maria Dolors Giménez, Carmen Márquez, Victoria Martin-Escudero, Pere Castellví, Ricard Navinés, Juan Ramon Castaño, Josep Anton Galeras, Esther Salas, Felipe Bory, Rocío Martín-Santos, Ricard Solà, A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C, Journal of Hepatology, 2013, 59, 5, 926

    CrossRef

  6. 6
    Mark S. Sulkowski, Fred Poordad, Michael P. Manns, Jean-Pierre Bronowicki, K. Rajender Reddy, Stephen A. Harrison, Nezam H. Afdhal, Heather L. Sings, Lisa D. Pedicone, Kenneth J. Koury, Vilma Sniukiene, Margaret H. Burroughs, Janice K. Albrecht, Clifford A. Brass, Ira M. Jacobson, Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial, Hepatology, 2013, 57, 3
  7. 7
    Vlad Ratziu, Jean-François Cadranel, Lawrence Serfaty, Jacques Denis, Christophe Renou, Patrick Delassalle, Carole Bernhardt, Gabriel Perlemuter, A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France, Journal of Hepatology, 2012, 57, 2, 376

    CrossRef

  8. 8
    F. Stickel, B. Helbling, M. Heim, A. Geier, C. Hirschi, B. Terziroli, K. Wehr, A. De Gottardi, F. Negro, T. Gerlach, Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C, Journal of Viral Hepatitis, 2012, 19, 2
  9. 9
    Martin Lagging, Ann-Sofi Duberg, Rune Wejstål, Ola Weiland, Magnus Lindh, Soo Aleman, Filip Josephson, Treatment of hepatitis C virus infection in adults and children: Updated Swedish consensus recommendations, Scandinavian Journal of Infectious Diseases, 2012, 44, 7, 502

    CrossRef

  10. 10
    EASL Clinical Practice Guidelines: Management of hepatitis C virus infection, Journal of Hepatology, 2011, 55, 2, 245

    CrossRef

  11. 11
    Gaetano Bertino, Annalisa Ardiri, Patrizia Maria Boemi, Giuseppe Stefano Calvagno, Irene Maria Ruggeri, Annalisa Speranza, Maria Milena Santonocito, Dario Ierna, Cosimo Marcello Bruno, Maria Valenti, Roberta Boemi, Simona Naimo, Sergio Neri, Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis, European Journal of Clinical Pharmacology, 2010, 66, 10, 1055

    CrossRef

  12. 12
    Mark S. Sulkowski, Mitchell L. Shiffman, Nezam H. Afdhal, K. Rajender Reddy, Jonathan McCone, William M. Lee, Steven K. Herrine, Stephen A. Harrison, F. Fred Poordad, Kenneth Koury, Weiping Deng, Stephanie Noviello, Lisa D. Pedicone, Clifford A. Brass, Janice K. Albrecht, John G. McHutchison, Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate, Gastroenterology, 2010, 139, 5, 1602

    CrossRef

  13. 13
    C. Falandry, M. Campone, G. Cartron, D. Guerin, G. Freyer, Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines, European Journal of Cancer, 2010, 46, 13, 2389

    CrossRef

  14. 14
    Katia Falasca, Claudio Ucciferri, Paola Mancino, Valeria Gorgoretti, Eligio Pizzigallo, Jacopo Vecchiet, Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response, Journal of Medical Virology, 2010, 82, 1
  15. 15
    John Koskinas, George Zacharakis, John Sidiropoulos, John Elefsiniotis, Savvas Savvas, Stamatia Kotsiou, Dimitrios Kountouras, Maria Schina, Panagiotis Kostopoulos, Athanasios Archimandritis, Granulocyte colony stimulating factor in HCV genotype-1 patients who develop Peg-IFN-α2b related severe neutropenia: A preliminary report on treatment, safety and efficacy, Journal of Medical Virology, 2009, 81, 5
  16. 16
    M. Bourliere, Traitement de l’hépatite C : gestion des effets secondaires, Gastroentérologie Clinique et Biologique, 2008, 32, 5, S166

    CrossRef

  17. 17
    Dominique Larrey, Patrice Couzigou, Jacques Denis, Hépatite chronique C : gestion des effets indésirables du traitement, Gastroentérologie Clinique et Biologique, 2007, 31, 8-9, 20

    CrossRef

  18. 18
    Howard J. Worman, Re-evaluating the use of growth factors as adjuvant treatment of chronic hepatitis C, Hepatology, 2007, 46, 4
  19. 19
    Thierry Thévenot, Vincent Di Martino, Françoise Lunel-Fabiani, Reply:, Hepatology, 2007, 46, 4
  20. 20
    Jean–Michel Pawlotsky, Treatment of Hepatitis C: Don’t Put All Your Eggs in One Basket!, Gastroenterology, 2007, 132, 4, 1611

    CrossRef